An online platform that offers public and private companies, across multiple industries the ability to stay active and engaged with the investment community.
In a #VirtualInvestor#KOLConnect segment, Dr. Ira Winer discusses the unmet need in ovarian cancer, the challenge of immunologically “cold” tumors and the potential of scalable, off-the-shelf engineered cell therapies.
🔗: vimeo.com/1199557462/89d514b…$ERNA
Dr. Toufic Kachaamy, Chief of Medicine at City of Hope Phoenix, joins a #WhatThisMeans segment to discuss the clinical significance of $AMIX’s data presented at the SSO Annual Meeting and its selection for a podium presentation.
🔗: vimeo.com/1198379906/a5ec75a…#MedTech
In a #WhatThisMeans segment, Tom Equels, Dr. Charles Lapp and Dr. Christopher Nicodemus, examine current Ebola outbreak concerns, the unmet need surrounding the Bundibugyo strain, and Ampligen’s previously published antiviral research.
🔗: vimeo.com/1198375699/68d52d4…$AIM#Ebola
In a #WhatThisMeans segment, Walter Klemp, CEO of $MBRX, discusses the enrollment of the 45th subject in Moleculin’s pivotal Phase 2B/3 MIRACLE trial evaluating AnnAraC for relapsed or refractory AML.
🔗Watch here: vimeo.com/1198377950/c532c11…
In a #VirtualInvestor#CEOConnect segment, Rami Levin highlights the Company’s recent strategic transformation progress, including its $22.5 million financing and pipeline development strategy focused on long-term shareholder value creation.
🔗: vimeo.com/1193965352/6cf0543…$CNSP
In a #KOLConnect segment, Professor Dr. Casper H.J. van Eijck joins CEO Tom Equels to discuss Ampligen’s potential in late-stage pancreatic cancer, highlighting its mechanism of action, clinical data, development strategy, and key regulatory milestones.
vimeo.com/1192236396/29dc789…
Virtual Investor KOL Connect: @ErnexaTx features CSO, Dr. Pierce, to discuss the ovarian cancer landscape, unmet need and the potential of their lead development asset to address limitations.